ISAB — Inhalation Sciences Sweden AB Income Statement
0.000.00%
- SEK47.63m
- SEK40.78m
- SEK17.50m
Annual income statement for Inhalation Sciences Sweden AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8.95 | 10.1 | 9.42 | 12.2 | 17.5 |
Cost of Revenue | |||||
Gross Profit | 5.82 | 6.76 | 5.22 | 9.64 | 14 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12 | -0.596 | 26 | 24.2 | 21.3 |
Operating Profit | -3.07 | 10.7 | -16.6 | -12 | -3.76 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4.34 | 9.88 | -16.6 | -12.1 | -4.74 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.34 | 9.88 | -16.6 | -12.1 | -4.74 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.34 | 9.88 | -16.6 | -12.1 | -4.74 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.34 | 9.88 | -16.6 | -12.1 | -4.74 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.06 | -1.11 | -1.66 | -1.07 | -0.357 |
Dividends per Share |